

**Review Form 1.6**

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_70206
Title of the Manuscript:	Development and Evaluation of Herbal Tablet Formulations of <i>Emblica officinalis</i> Gaertn. Leaf Extract
Type of the Article	

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

**Review Form 1.6**

**PART 1: Review Comments**

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Compulsory</b> REVISION comments	<ul style="list-style-type: none"> <li>. The overall manuscript is not properly presented and written.</li> <li>. The objective of manuscript is not clearly mentioned.</li> <li>. As per author instruction, no information provided for Institutional Review Board (IRB) or Ethical Committee, for Animal study/utilization.</li> <li>. Introduction part contained some repetitive text.</li> <li>. Numerous activities have been reported for the selected plant, hence need to be include relevant literature review.</li> <li>. In tablet formulation, apart from presented evaluation criteria, other important criteria also need to incorporate like density, H. ratio, flow property etc.</li> <li>. The compatibility of API/excipients study can be well established by thermal method like DSC.</li> <li>. The IR data interpretation may be improved.</li> <li>. The quality of FTIR spectra need to improve.</li> <li>. In presented work author only described regarding gallic acid, what about other constituents?</li> <li>. No rational has been cited for the selected experimental design.</li> </ul>	
<b>Minor</b> REVISION comments	<ul style="list-style-type: none"> <li>. It will be more acceptable to present the overall tablet formulation with flow chart/ figure etc.</li> <li>. Short form/name whenever used in text, it should be first introduced by full name and followed by short form.</li> <li>. Some tables are of no use and can be omitted.</li> <li>. Number of references can be improved with relevant citation.</li> <li>. The values of standard deviation in many cases are not convincing.</li> <li>. Which internal standard was used? Why?</li> <li>. What is CFR–21-part II software?</li> </ul>	
<b>Optional/General</b> comments		

[Review Form 1.6](#)

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i> Yes, regarding animal study- Institutional ethics committee approval is mandatory but it is not presented.	

**Reviewer Details:**

Name:	<b>N. H. Vadia</b>
Department, University & Country	<b>Saurashtra University, India</b>